Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.

Science advances·2026
Same author

Nanomedicine and Biomaterial Platforms for Photoimmunotherapy.

Angewandte Chemie (International ed. in English)·2026
Same author

Engineering Polymer-Lipid Integrated Nanoparticles with Quantitative Design Principles for Organ-Selective mRNA Delivery.

Journal of the American Chemical Society·2026
Same author

CaCO<sub>3</sub>-assisted engineering of NIR-II phototheranostics enables photothermally enhanced ferroptosis in cancer through synergistically depleting intracellular glutathione.

Nanoscale horizons·2026
Same author

Vascular-Mimetic 2D Membranes with Hemoglobin Catalysis for Efficient Uranium Extraction.

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

Inhalation of Mesenchymal-Stem-Cell-Derived Nanovesicles Delivering Catalase Enhances the Treatment for Acute Lung Injury.

ACS nano·2025

Related Experiment Video

Updated: Jun 11, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy.

Feifei Zhang1, Zhencun Cui2, Haidong Li1

  • 1MOE Frontiers Science Center for Rare Isotopes and State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou 730000, China.

ACS Nano
|June 9, 2026
PubMed
Summary

A novel nanoplatform, TRT@LnOMVs, enhances targeted radionuclide therapy (TRT) and immunotherapy by reprogramming the tumor microenvironment. This radio-immunotherapy approach significantly improves survival rates in prostate cancer models.

Keywords:
lanmodulinouter membrane vesiclesradio-immunotherapytargeted radionuclide therapytumor microenvironment

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 11, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Immunology

Background:

  • Targeted radionuclide therapy (TRT) combined with immunotherapy shows promise for cancer treatment.
  • Developing adaptable delivery platforms for synergistic radio-immunotherapy is challenging.
  • Current methods for radiolabeling face limitations.

Purpose of the Study:

  • To develop a programmable, "plug-and-play" nanoplatform for synergistic radio-immunotherapy.
  • To enable versatile and efficient radiolabeling of diverse therapeutic radioisotopes.
  • To investigate the potential of this platform in overcoming current therapeutic challenges.

Main Methods:

  • Engineered outer membrane vesicles (OMVs) from *Salmonella typhimurium* displaying lanmodulin (LanM).
  • Facile radiolabeling of diverse isotopes under mild conditions.
  • Incorporated lipid-conjugated ligands for precision targeting.
  • Utilized single-cell RNA sequencing and transcriptomic analysis to study tumor immune microenvironment remodeling.

Main Results:

  • TRT@LnOMVs demonstrated high-efficiency radiolabeling and modular targeting.
  • PSMA-targeted TRT@LnOMVs achieved a 90% survival rate in a prostate cancer model, outperforming 177Lu-PSMA-617 (25% survival).
  • TRT@LnOMVs significantly remodeled the tumor immune microenvironment by reprogramming myeloid cells, enhancing cytotoxic T and NK cell infiltration, and activating innate immunity.

Conclusions:

  • TRT@LnOMVs represent a versatile class of biohybrid therapeutics.
  • This platform offers a robust paradigm for next-generation radio-immunotherapy.
  • The nanoplatform effectively synergizes targeted radionuclide therapy and immunotherapy for enhanced antitumor responses.